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Abstract Previous studies examining communication of
BRCA1/2 results with relatives and family uptake of
BRCA1/2 testing have sampled from predominantly white,
high SES cohorts ascertained solely from tertiary care centers.
No studies have focused on family communication and testing
among relatives of diverse BRCA1/2 carriers. We conducted
structured interviews with 73 BRCA1/2 carriers identified at a
public hospital and a tertiary cancer center. We asked partici-
pants if each first- and second-degree relative was aware of
their BRCA1/2 results and whether or not each relative had
tested. Generalized estimating equations identified rates and
predictors of family communication and testing. Participants
disclosed their test results to 73 % of 606 eligible relatives and
31 % of 514 eligible relatives tested. Communication and
testing rates were similar for relatives of participants from the
public hospital and the tertiary cancer center. Hospital site was
not a significant predictor of either result disclosure or relative
uptake of testing. African American and Asian/Pacific Islander
participants were significantly less likely to disclose their re-
sults to their relatives; relatives of African American partici-
pants were significantly less likely to test. Addressing these
disparities will require further research into the best ways to
facilitate family communication and counsel at-risk relatives of
racially and socioeconomically diverse BRCA1/2 mutation
carriers.
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Introduction
BRCA1/2 testing has become standard of care for families at
high risk of hereditary breast and ovarian cancer syndrome
(HBOC) (Berliner and Fay 2007; Lu et al. 2009; NCCN 2011;
Robson et al. 2010; USPSTF 2005). After a deleterious
BRCA1/2 mutation has been identified in a family, the index
(first-identified) mutation carrier is primarily responsible for
the next step of family communication. This involves dissem-
inating his or her genetic test result to at-risk relatives and
encouraging appropriate relatives to test (Offit et al. 2004).
Additional relatives who subsequently test positive are also
encouraged to disclose their results to other at-risk relatives.
If relatives decide to pursue BRCA1/2 testing, several
potential benefits emerge. Perhaps most importantly, testing
allows relatives to clarify their personal risk of HBOC-
associated cancers. Relatives who test positive for the family
mutation can take advantage of screening, prevention, and
risk-reduction interventions to decrease the risk of HBOC-
associated cancers and overall mortality (Burke et al. 1997;
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Domchek et al. 2010; Nathanson and Domchek 2011;
Rebbeck et al. 2009). Relatives who test negative for the
family mutation are at no higher risk of breast and ovarian
cancer than the general population (Harvey et al. 2011; Kauff
et al. 2005; Kurian et al. 2011). In the United States, testing for
a known family mutation is also considerably less expensive
than full sequencing of BRCA1/2 (Plon et al. 2011).
Previous studies have found that the index (first-identified)
carrier in a family shares their results with 84–96 % of first-
degree relatives (Blandy et al. 2003; Finlay et al. 2008;
Hughes et al. 2000; MacDonald et al. 2007; McGivern et al.
2004; Wagner-Costalas et al. 2003). In one study, 59 % of
first-degree, second-degree relatives, and cousins were told
about positive results (McGivern et al. 2004). BRCA1/2 car-
riers are more likely to disclose results to female and first-
degree relatives and less likely to disclose results to elderly
relatives (Claes et al. 2003; MacDonald et al. 2007; McGivern
et al. 2004; Patenaude et al. 2006; Wagner-Costalas et al.
2003). Barriers to communication of BRCA1/2 results include
lack of contact and emotionally distant relationships (Hughes
et al. 2000; McGivern et al. 2004; Landsbergen et al. 2005).
Rates of BRCA1/2 testing in at-risk relatives are fairly low;
only 15–51 % of all first- and second-degree relatives test for
known family mutations (Blandy et al. 2003; Finlay et al.
2008; Landsbergen et al. 2005; MacDonald et al. 2007;
McGivern et al. 2004). In one study, 40% ofBRCA1/2 carriers
reported that none of their relatives had tested (Claes et al.
2003). Similar to family communication of results, female and
first-degree relatives are more likely to uptake BRCA1/2 test-
ing (Blandy et al. 2003; McGivern et al. 2004). Members of
cohesive families, as well as older individuals, are more likely
to pursue BRCA1/2 testing for a previously identified family
mutation (Biesecker et al. 2000).
Few studies have examined predictors of family commu-
nication and BRCA1/2 testing in diverse populations.
Almost all studies on this topic have been done among
predominantly white, high socioeconomic status cohorts
ascertained from tertiary cancer centers which did not select
for racially and socioeconomically diverse BRCA1/2 muta-
tion carriers (Blandy et al. 2003; Finlay et al. 2008; Hughes
et al. 2000; MacDonald et al. 2007; McGivern et al. 2004;
Wagner-Costalas et al. 2003).
One study reported that relatives of BRCA1/2 carriers
identified at public hospitals may be less likely to pursue
family testing than relatives of BRCA1/2 carriers from ter-
tiary cancer centers, and that relatives of African American
and Asian BRCA1/2 carriers are also less likely to test
(Cheung et al. 2010). This study, however, was not specifical-
ly designed to examine racial or hospital site predictors. It also
did not examine pedigrees of BRCA1/2 testers and was there-
fore unable to report the overall number of at-risk relatives or
family communication and testing rates in these relatives
(Cheung et al. 2010).
As BRCA1/2 testing becomes more common in diverse
populations, it is increasingly important to examine family
communication and testing in diverse families. To our knowl-
edge, this study is among the first specifically designed to
examine family communication and testing in a diverse popu-
lation that includes BRCA1/2 testers at a public hospital and a
tertiary cancer center. The specific aims of this study were to
(1) calculate rates of BRCA1/2 result disclosure and testing
uptake among eligible relatives, (2) determine predictors of
BRCA1/2 result disclosure to relatives and BRCA1/2 testing of
at-risk relatives in a diverse sample of BRCA1/2 carriers,
and (3) to examine the independent predictive value of
race/ethnicity on family communication and testing.
Materials and Methods
Study Population
We identified participants who had tested positive for a
germline BRCA1/2 mutation and had enrolled in the
University of California San Francisco Cancer Risk
Program’s (CRP) IRB-approved follow-up protocol (Lee et
al. 2005). The CRP provides genetic counseling and testing at
two sites: San Francisco General Hospital (SFGH), a safety
net, county hospital, and the Mt. Zion location of the Helen
Diller Family Comprehensive Cancer Center (Mt. Zion), a
tertiary referral center. Both sites use the same clinical staff
and threshold for genetic testing. At SFGH, genetic counsel-
ing and testing are provided free of charge to patients if they
are uninsured or if their insurance does not cover genetic
testing. For relatives of known BRCA1/2 carriers, both sites
provide genetic counseling and single site family mutation
testing regardless of a patient’s ability to pay.
Participants were considered eligible if they underwent both
counseling and testing with the CRP, had a life expectancy of at
least 6 months at the time of the survey, had no significant
history of mental illness, were currently living in the United
States, and were conversant in English or Spanish. If more than
one individual from a family had tested with the CRP, we
attempted to contact the first family member who had tested.
We did not limit participation to probands because we wanted
to collect as many outcomes as possible in this understudied
population. We surveyed one individual per family, however,
so as not to double count outcomes for individuals in a family
where more than one person had BRCA1/2 tested with the CRP.
We applied this eligibility criteria to all BRCA1/2 carriers
who tested at SFGH, all non-white BRCA1/2 carriers identified
at Mt. Zion, and a random sample of white BRCA1/2 carriers
identified at Mt. Zion between January 2003 and August 2011.
We did not include all whiteBRCA1/2 carriers fromMt. Zion in
our study population because family communication and
family testing outcomes have been previously studied in
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white women identified at tertiary cancer centers similar
to Mt. Zion.
We identified the following numbers of BRCA positive
families: 26 families from SFGH, 56 non-white families from
Mt. Zion, and 246 white families from UCSF. Three families
from SFGH and five non-white families fromMt. Zion did not
meet the study eligibility criteria. We collected outcomes in 17
families from SFGH (3 African American, 3 Asian/Pacific
Islander, 3 Hispanic, and 8 white) and 33 non-white families
from Mt. Zion. Assuming a non-response rate of 30 %, we
used a random number generator to identify 35 white families
from Mt. Zion, and 24 of these were interviewed. Our overall
survey response rate was 67 % (78 % from SFGH, 65 % from
non-white families identified at Mt. Zion and 69 % among the
sample of white families identified at Mt. Zion).
Procedures
We contacted all eligible participants by phone or e-mail from
September 2011 to January 2012 and invited them to partici-
pate in a 15–20 min structured interview. Eligible participants
with working emails received a brief electronic description of
the study and were asked to respond if they were interested in
participating. Email non-responders and eligible participants
without working emails received phone calls. If we were un-
able to reach eligible participants after three phone attempts, we
did not contact them further. Study participants from both sites
were sent a grocery-card incentive (twenty-five dollars for
SFGH participants and ten dollars for Mt. Zion participants).
Study participants completed the interview by phone, in
person, or by e-mail, based on their preference. We contacted
participants a minimum of 3 months after receiving positive
BRCA1/2 results. This allowed time to communicate results
with relatives and to begin the family testing process.
During the interviews, we used each participant’s pedi-
gree to verify family structure and identify eligible relatives
for sharing and testing. Our study instrument, the Family
Communication Questionnaire (Kardashian et al. 2012), was
pilot-tested in a sample of 19 BRCA1/2 carriers from Mt.
Zion in 2010. In order to sample a more diverse population, a
professional translator translated the Family Communication
Questionnaire into Spanish. We conducted interviews in
both English and Spanish. All participants provided in-
formed consent and this study was approved by our institu-
tion’s IRB.
Measures
Participant Characteristics
For each participant, we recorded hospital testing site, self-
reported race/ethnicity, Ashkenazi Jewish ancestry, whether or
not the participant was born in the United States, education
(categorized as less than high school graduate, high school
graduate, college graduate, or completed a postgraduate
degree), employment status (employed or not employed),
medical insurance status (categorized as public insurance,
private insurance, or uninsured), date of results, date of
birth, and personal history of breast and/or ovarian cancer.
We queried participant’s understanding of which parent they
had inherited their mutation from with the text “often, a
BRCA1/2 mutation is passed down from either your mother’s
or your father’s side of the family” followed by the questions:
“Do you know what side of the family your mutation comes
from? If so, how do you know?” This question was included in
an attempt to only measure outcomes among relatives on the
same side of the family the participant had inherited their
mutation from and to adjust the denominator for eligible rela-
tives accordingly. We also asked participants if they had tested
for a BRCA1/2 mutation previously identified in their family
and if so, how they had found out about the family mutation,
and how long it took them to test. For those relatives of study
participants that tested within the CRP, we found that all
participants had correctly reported their relative’s test results.
Relative Characteristics
For each eligible first- and second-degree relative included
on the participant’s pedigree, we asked the participant to
identify the relative’s gender, relationship to participant,
age, frequency of communication with participant (dichoto-
mized as at least once a month or less than once a month),
and whether or not the relative lives in the United States.
Inclusion criteria for relatives in analyses of family commu-
nication and testing were based on eligibility criteria from
consensus guidelines of the National Society of Genetic
Counselors and the National Comprehensive Cancer
Network (Berliner and Fay 2007; NCCN 2011).
Family Communication of BRCA1/2 Results
For each eligible first-and second-degree relative, we asked
participants “To your knowledge, does he/she know about
your BRCA1/2 mutation?” Relatives eligible for sharing were
at least 16 years old at the time of the survey and on the same
side of the family the participant had inherited the mutation
from (if known). If the participant did not know which side of
the family they had inherited their mutation from, we asked
about both maternal and paternal relatives. Our consent pro-
cess did not allow us to directly contact relatives to verify
participant reports of family communication or testing.
Family BRCA1/2 Testing
We asked participants if each of their eligible first- and
second-degree relatives had undergone BRCA1/2 testing
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with the question, “To your knowledge, has this relative
tested for a BRCA1/2 mutation?” Relatives eligible for test-
ing were at least 25 years old at the time of the survey and
had at least a 25 % chance of carrying the mutation identi-
fied in the family (50 % if they were a first-degree relative
and 25 % if they were a second-degree relative). This meant
that some relatives were eligible for sharing, but not for
testing, even if they were at least age 25 at the time of the
survey. For example, if a participant’s sister tested negative
for the family mutation and had a 30-year old daughter, we
considered this niece eligible for sharing, but not for testing.
As the niece of the known carrier, but the daughter of a non-
carrier, she cannot inherit the family mutation and is there-
fore not eligible for family BRCA1/2 testing. We chose age
25 as the cut-off point for testing eligibility because that is
the youngest age at which cancer screening is recommended
if the relative tests positive (NCCN 2011). If relatives had
tested, we asked whether they tested before or after the
participant. If the relative tested after the participant, the
study interview queried the amount of time that elapsed
between knowing of the family mutation and testing.
Study data was entered at the time of interview and
stored in a secure, password-protected RedCap database
hosted at the University of California San Francisco
(Harris et al. 2009).
Statistical Analysis
We first generated descriptive statistics to characterize both
the participants and the relatives in our sample. Next, we
used chi square tests to compare rates of family communi-
cation and testing among relatives. Finally, to account for
family clusters, we used generalized estimating equations to
identify bivariate and multivariate predictors of eligible
relatives knowing about the participant’s BRCA1/2 mutation
and uptake of BRCA1/2 testing by eligible relatives. Because
our primary outcomes were assessed in individual relatives,
rather than study participants, our n for the bivariate and
multivariate models was based on the number of eligible rela-
tives for family communication and testing, respectively.
Variables with p <0.2 in bivariate models for testing were
considered for inclusion in the final multivariate models of
family communication and testing. The multivariate model
controlled for relative gender, degree of relationship, whether
the relative lives in the United States, frequency of communi-
cation with participant, hospital site, and participant
race/ethnicity, education level (dichotomized as high school
graduate or less or more than high school graduate), testing
for a known family mutation, and participant history of breast
and/or ovarian cancer. The model for testing also controlled for
communication of results to the relative. All tests were two-
tailed with α=0.05. Statistical analyses were conducted in
SAS.
Results
Participant Characteristics
Participant demographic and clinical characteristics are
shown in Table 1. Our study population was racially diverse
(by design): 10 % African American, 19 % Asian/Pacific
Islander, 23 % Hispanic, 44 % white, and 4 % mixed race.
The mean age of participants at testing was 47.4 (SD 12.4)
years. Participants received BRCA1/2 results a mean of
Table 1 Baseline background and health history characteristics of
study participants
Total (N=73)
Background characteristics
Testing site, n (%)
San Francisco General Hospital 17 (23 %)
Mt. Zion 56 (77 %)
Race/Ethnicity, n (%)
African American 7 (10 %)
Asian/Pacific Islander 14 (19 %)
Hispanic 17 (23 %)
White 32 (44 %)
Mixed 3 (4 %)
Ashkenazi Jewish, n (%) 15 (21 %)
Born outside the United States, n (%) 17 (23 %)
Education, n (%)
Did not complete high school 6 (8 %)
Completed high school 16 (22 %)
Completed college 30 (41 %)
Completed postgraduate degree 21 (29 %)
Employment status, n (%)
Employed 45 (62 %)
Not employed 28 (38 %)
Insurance, n (%)
Public insurance 18 (24 %)
Private insurance 52 (70 %)
Uninsured 3 (4 %)
Number of first-degree relatives, mean (SD)a 3.6 (2.3)
Number of second-degree relatives, mean (SD)a 4.8 (5.1)
Health history
Age at testing, years, mean (SD) 47.4 (12.4)
Time since testing, years, mean (SD) 2.8 (2.5)
History of breast/ovarian cancer, n (%)
None 28 (38 %)
Breast cancer 36 (49 %)
Ovarian cancer 8 (11 %)
Both breast and ovarian cancer 1 (1 %)
Tested for known family mutation, n (%) 33 (46 %)
a Among relatives eligible for communication of BRCA1/2 results
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2.8 years prior to survey (range 0.2–8.6 years, SD 2.5 years).
The majority of participants reported either breast or ovarian
cancer: 49 % had a history of breast cancer, 11 % a history
of ovarian cancer, and 1 participant (1 %) was affected by
both. Of 73 participants, 81 % reported knowing whether
they inherited the mutation from their maternal or paternal
relatives, and 46 % had tested for a known family mutation.
Relative Characteristics
Overall, participants reported 606 relatives eligible for sharing
and 514 relatives eligible for testing. Among relatives eligible
for sharing, 263 were first-degree relatives, 305 were female,
497 lived in the United States, and 289 communicated with
the participant at least once a month.
Family Communication and Testing Rates
Participants reported that 73 % of first- and second-degree
relatives knew about their BRCA1/2 mutation. As shown in
Table 2, eligible relatives were more likely to know about the
participant’s BRCA1/2 mutation if they were first-degree,
female, living in the United States, and communicated with
the participant at least once a month. Among relatives who
knew about the participant’s BRCA1/2 mutation, most found
out within a week (Fig. 1).
Only 31 % of all eligible relatives underwent BRCA1/2
testing, however. Similar to family communication, first-
degree relatives, female relatives, relatives living inside the
United States and relatives who communicated with the par-
ticipant at least once a month were significantly more likely to
BRCA1/2 test (Table 3). Of the 158 relatives who underwent
BRCA1/2 testing, 66 (42 %) had tested before the participant,
and 92 tested after the participant. Among those who tested
after the participant, most tested within 1 year (Fig. 2).
Predictors of Family Communication and Testing
After adjusting for relative and participant characteristics,
only degree of relationship and frequency of communication
with participant independently predicted whether or not the
participant’s mutation had been disclosed to the relative
(Table 2). African American and Asian/Pacific Islander
participants were less likely to disclose their mutation status
to their relatives compared to white participants. No other
participant characteristics were significantly associated with
communication of BRCA1/2 results to relatives. There were
no significant interactions between relative gender, degree
of relationship, whether the relative lives in the United
States, frequency of communication with participant, hospi-
tal site, participant race/ethnicity, education level, testing for
a known family mutation, or participant history of breast
and/or ovarian cancer in the family communication model.
Relatives were more likely to undergo genetic testing if
they were first-degree, female, or lived in the United States
(Table 3). If the participant had not disclosed their mutation
status to a relative, that relative was significantly less likely
to BRCA1/2 test. In the multivariate testing model, we
identified significant interactions between the relative’s de-
gree of relationship to the participant and frequency of
communication, so we stratified by degree of relationship
for frequency of communication. In this stratified model,
first-degree relatives who communicated with the partici-
pant at least once a month were significantly more likely to
have undergone BRCA1/2 testing. Relatives of African
American participants were significantly less like to test
than relatives of white participants.
Discussion
To our knowledge, this is the first study to examine family
communication and family testing uptake among a racially
and socioeconomically diverse population of BRCA1/2 mu-
tation carriers. This study found similar rates of family
communication with relatives (73 % overall) compared to
prior research. This is reassuring, given the demographic
differences between our cohort and the majority white
populations surveyed in other studies. BRCA1/2 testing rates
among eligible relatives in this study (31 %) were also
similar to family testing rates in other studies (range 15–
51 %). However, it is difficult to directly compare results
from this study with prior research that queried testing
among slightly different populations of relatives based on
degree of relationship, gender, and age (Finlay et al. 2008;
Hughes et al. 2000; MacDonald et al. 2007; Patenaude et al.
2006). Importantly, this study identifies several novel pre-
dictors of family communication and testing, particularly
with respect to race. Because this study was specifically
designed to include a racially diverse population, our findings
can build upon prior work regarding BRCA1/2 testing and
family communication in diverse populations (Armstrong et
al. 2003; Armstrong et al. 2005; Barlow-Stewart et al. 2006;
Haffty et al. 2009; Hughes et al. 2003; Kurian et al. 2008;
Lerman et al. 1999; Susswein et al. 2008; Thompson et al.
2003; Yoon et al. 2011).
In this study, African American participants were less
likely to disclose their results to relatives, who were subse-
quently less likely to test. Rates of genetic counseling and
testing uptake have historically been lower in African
Americans compared to whites, although this may be atten-
uated in African American women with a recent diagnosis
of breast cancer (Armstrong et al. 2003, 2005; Susswein et
al. 2008). Qualitative interviews with African American
women have identified genetic discrimination, abuses of
genetic testing results, and medical mistrust as barriers to
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BRCA1/2 testing (Hughes et al. 2003; Thompson et al.
2003). Enhanced pre-testing education and counseling,
however, have been associated with increased testing uptake
among African American women (Lerman et al. 1999).
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Timing of Communication of BRCA1/2 Results to
Eligible Relatives
Fig. 1 Timing of Communication
of BRCA1/2 Results to Eligible
Relatives. a Of 439 relatives to
whom the participant’s mutation
was disclosed, participants did not
remember when BRCA1/2 results
were communicated to 106
relatives. b Relatives were
eligible for communication of
BRCA1/2 results if they were at
least age 16 and had at least a
25 % chance of carrying the
participant’s BRCA1/2 mutation
Table 2 Rates and adjusted
predictors of BRCA1/2 result
disclosure to eligible relatives
(Relatives eligible for sharing
were at least 16 years old
at the time of the survey and on
the same side of the family the
participant had inherited the
mutation from (if known)) based
on relative and participant
characteristics
*p<0.05 **p<0.01
aModel controlled for relative’s
degree of relationship to partici-
pant, gender, frequency of
communication with participant,
if relative lives in the United
States, as well as the participant’s
testing site, race/ethnicity, educa-
tion level, personal cancer history,
and whether or not they tested
for a known family mutation
N (%) Adjusted OR (95 % CI)a
Relative characteristics
Degree of relationship
Second-degree relative 198 (58 %)** Ref
First-degree relative 243 (93 %) 4.1 (1.4 – 11.7)**
Relative gender
Male 202 (67 %)* Ref
Female 241 (79 %) 1.63 (0.84 – 3.2)
Frequency of communication with participant
Less than once a month 151 (52 %)** Ref
Once a month or more 269 (93 %) 7.3 (3.2 – 17.0)**
Where relative lives
Outside United States 64 (59 %)** Ref
Inside United States 379 (76 %) 1.2 (0.45 – 3.3)
Participant characteristics
Where participant tested
Mt. Zion 306 (80 %) Ref
SFGH 137 (82 %) 1.8 (0.63 – 5.1)
Participant race/ethnicity
White 135 (91 %)** Ref
African American 53 (47 %) 0.15 (0.05 – 0.45)**
Asian/Pacific Islander 117 (70 %) 0.18 (0.07 – 0.49)**
Hispanic 123 (84 %) 1.1 (0.23 – 4.8)
Mixed 15 (80 %) 0.86 (0.10 – 7.5)
Participant education level
High school graduate or more 379 (81 %) Ref
Less than high school graduate 64 (77 %) 0.87 (0.27 – 2.8)
Personal cancer history
None 178 (83 %) Ref
Breast/ovarian cancer or both 265 (80 %) 0.66 (0.11 – 4.0)
Tested for known family mutation
No 222 (78 %) Ref
Yes 221 (84 %) 0.85 (0.14 – 5.4)
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Table 3 Rates and adjusted
predictors of BRCA1/2 testing
among eligible relatives
(Relatives eligible for testing
were at least 25 years old at the
time of the survey and had at
least a 25 % chance of carrying
the mutation identified in the
family) based on relative and
participant characteristics
*p<0.05 **p<0.01
aModel controlled for relative’s
degree of relationship to partici-
pant, gender, frequency of
communication with participant,
if relative lives in the United
States, as well as the
participant’s testing site, race/
ethnicity, education level,
personal cancer history, and
whether or not they tested for
a known family mutation
bModel stratified by degree of
relationship. Odds ratio
represents adjusted odds of
testing among first-degree
relatives who communicate with
the participant at least once
a month
N (%) Adjusted OR (95 % CI)a
Relative characteristics
Degree of relationship
Second-degree relative 55 (20 %)** Ref
First-degree relative 103 (43 %) 0.66 (0.25 – 1.8)
Relative gender
Male 36 (14 %)** Ref
Female 122 (47 %) 8.2 (4.8 – 13.8)**
Frequency of communication with participant
Less than once a month 46 (19 %)** Ref
Once a month or more 103 (40 %) 5.1 (1.1 – 22.9)c
Where relative lives
Outside United States 10 (12 %)** Ref
Inside United States 148 (35 %) 6.0 (1.6 – 22.8)**
BRCA1/2 result disclosedb
Yes – Ref
No 0.16 (0.05 – 0.57)**
Participant characteristics
Where participant tested
Mt. Zion 121 (38 %) Ref
SFGH 37 (32 %) 1.4 (0.63 – 3.2)
Participant race/ethnicity
White 63 (44 %)* Ref
African American 7 (6 %) 0.16 (0.06–0.40)**
Asian/Pacific Islander 36 (27 %) 0.68 (0.20 – 2.4)
Hispanic 40 (34 %) 1.9 (0.48 – 7.3)
Mixed 12 (68 %) 7.8 (1.8 – 34.0)
Participant education level
High school graduate or more 147 (38 %) Ref
Less than high school graduate 9 (17 %) 0.40 (0.15–1.1)
Personal cancer history
None 84 (47 %) Ref
Breast/ovarian cancer or both 74 (30 %) 0.55 (0.19 – 1.54)
Tested for known family mutation
No 59 (25 %) Ref
Yes 99 (50 %) 1.64 (0.57 – 7.5)
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Timing of BRCA1/2 Testing Among Eligible RelativesFig. 2 Timing of BRCA1/2
Testing Among Eligible
Relatives. a Of the 158 eligible
relatives tested, participants
were unsure when 12 relatives
underwent BRCA1/2 testing.
b Relatives were eligible for
BRCA1/2 testing if they were at
least age 25 at the time of
the survey and had at least a
25 % chance of inheriting the
participant’s BRCA1/2
mutation
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Relatives of Asian/Pacific Islander participants were also
significantly less likely to disclose their BRCA1/2 results in
this study, although they were not significantly less likely to
pursue BRCA1/2 testing. This confirms the findings of
Cheung and colleagues, who found that Asian BRCA1/2
testers were less likely to communicate their results to their
relatives and that their relatives were less likely to test
(Cheung et al. 2010). Among Asian/Pacific Islanders at risk
of HBOC, family histories and perceptions of hereditary
cancer risk may be inaccurate and relatives may be reluctant
to discuss cancer (Barlow-Stewart et al. 2006; Yoon et al.
2011). This may make BRCA1/2mutation prediction models
that rely on family cancer history less accurate in Asian
Americans (Kurian et al. 2008). Among women diagnosed
with breast cancer before age 45, for example, Korean
women are more likely to have no family history of cancer,
and to test positive for a deleterious BRCA1/2 mutation in
the absence of a family history (Haffty et al. 2009).
Family communication of BRCA1/2 results was equally
likely among relatives who live in the United States com-
pared to other countries, but relatives in the United States
were significantly more likely to test. Although BRCA1/2
testing is widely available in the United States, Canada,
Europe, Israel, and Australia/New Zealand, testing done in
many other countries is performed mainly for research pur-
poses or is unaffordable for most of the population (De Leon
Matsuda et al. 2002; Narod 2009; Yoon et al. 2011).
Innovative approaches to increase BRCA1/2 testing among
relatives of BRCA1/2 mutation carriers living outside coun-
tries where testing is widely available are urgently needed.
Practice Implications
Although rates of communication about positive BRCA1/2
results were high, particularly for first-degree relatives, not
all relatives learned of the family mutation. Educational
materials provided during the results disclosure process
could help facilitate this process (Kardashian et al. 2012;
Ratnayake et al. 2011). At our institution, we provide newly
identified BRCA1/2 carriers with the Sharing Risk Information
Tool (ShaRIT). ShaRIT includes a family letter, mutation re-
port, risk-reduction and surveillance guidelines, and contact
information for genetic counselors and therapists near where
relatives live, and has been well-received by patients
(Kardashian et al. 2012). Given our observation of lower odds
of family communication among relatives of African American
and Asian participants, culturally targeted counseling protocols
and educational materials should be developed and evaluated to
facilitate family communication and family uptake ofBRCA1/2
testing among relatives of patients from these backgrounds
(Ratnayake et al. 2011).
Strengths of this study include the racial and socio-
economic diversity of participants, the long follow-up time
after receiving BRCA1/2 results (mean 2.8 years), and the
fact that all participants were counseled and tested within
the same genetic counseling program. Our survey response
rate was acceptable (67 %), particularly in this diverse
population, and we captured the majority of BRCA1/2 car-
riers at both SFGH and Mt. Zion by offering the survey in
both English and Spanish. Only three (3 %) eligible
BRCA1/2 carriers were excluded by limiting the survey to
these two languages. While we only interviewed 73
BRCA1/2 carriers, our study design allowed us to collect
outcomes in over 600 relatives eligible for communication
of BRCA1/2 results and over 500 relatives eligible for
BRCA1/2 testing.
Study Limitations
Several limitations of this study are worth noting. We did
not directly contact relatives to verify participant reports of
family communication and testing, so true rates of family
communication and testing may differ from those reported
by participants. Most other studies that have examined fam-
ily communication and testing outcomes among BRCA1/2
carriers, however, have followed a similar approach and our
consent process did not allow us to directly contact relatives.
Because we could not directly contact relatives, we were
unable to assess their recollections of how results were
communicated, the implications of carrying a BRCA1/2
mutation, or whether they themselves had undergone genetic
counseling, but not testing (Sermijn et al. 2004; Vos et al.
2011). Future studies on this topic would benefit from
interviewing relatives of diverse BRCA1/2 carriers to confirm
the disclosure of BRCA1/2 results. Interviewing relatives di-
rectly would allow for an examination of relatives’ decision-
making process on whether or not to pursue BRCA1/2 testing,
and explore topics that probandswould not necessarily be able
to address, such as insurance status and the relative’s concerns
about the implications of testing.
Our eligibility criteria for result disclosure may underes-
timate family communication rates in our population. We
considered relatives aged 16 and over to be eligible for
BRCA1/2 result disclosure. Other studies have considered
children as young as 6 years (MacDonald et al. 2007) or
12 years (Claes et al. 2003) to be eligible for results disclo-
sure, while other studies did not specify inclusion criteria
based on age (Hughes et al. 2000; McGivern et al. 2004;
Finlay et al. 2008). Including relatives 16–20 years of age
may underestimate result disclosure rates. A majority of
participants, however, had a history of breast or ovarian
cancer, so we suspect that many children ages 16–20 would
have been informed of the results given the history of cancer
in the family. Furthermore, we considered children of family
members who had tested negative to be eligible for sharing
but not for testing. We chose to include these relatives
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because we felt the benefits of knowing about the partici-
pant’s mutation (and their parent’s negative result) would be
useful to evaluate their personal risk of BRCA-associated
cancers. Including these relatives in the denominator for
sharing may have decreased sharing rates, and our survey
instrument did not query whether or not participants felt
they needed to communicate their results to relatives not at
risk of carrying a mutation.
We also acknowledge the potential for selection bias. The
BRCA1/2 carriers we contacted who completed the survey
may have higher rates of sharing and testing compared to
non-participants. Although we included participants from a
safety-net hospital and a tertiary cancer center, both SFGH
and Mt. Zion are affiliated with the University of California
San Francisco’s Cancer Risk Program. Future studies should
compare family communication and family BRCA1/2 test-
ing between safety-net hospitals, unaffiliated tertiary cancer
centers, and community-based settings.
Research Recommendations
Despite these limitations, this study identifies several impor-
tant predictors of family communication and family member
uptake of BRCA1/2 testing. In this population, relatives of
African American and Asian/Pacific Islander BRCA1/2 muta-
tion carriers were less likely to know about BRCA1/2 test
results. Furthermore, relatives of African American partici-
pants were less likely to test for the family mutation, as were
relatives living outside the United States. Addressing these
disparities will require novel approaches to educating individ-
uals at high risk of HBOCwho present for genetic counseling,
making genetic testing available to their relatives, and re-
search into the best ways to facilitate family communication
and family testing among relatives of racially and socioeco-
nomically diverse BRCA1/2 mutation carriers.
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